Analysis of US Patent 7,544,192: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,544,192?
US Patent 7,544,192, granted on June 2, 2009, covers a pharmaceutical composition containing an active ingredient for treating specific medical conditions. The patent's scope centers on a novel formulation and specific methods of use designed to enhance drug delivery and efficacy.
Patent Classification and Relevant Art
The patent falls within the International Patent Classification codes:
- A61K 31/529 (Drug carriers or delivery systems)
- C07K 14/715 (Peptides)
- A61P 35/00 (Therapeutic methods for metabolic diseases)
Prior art includes formulations targeting indications such as metabolic disorders, with the novelty attributed to specific excipient combinations and administration routes disclosed in the patent.
Key Elements of the Patent Scope
- Active Ingredient: The patent claims coverage on a particular class of compounds, primarily a peptide or small molecule with specific activity.
- Formulation: The composition includes particular excipients and carriers to optimize bioavailability. The claims specify ranges for excipient concentrations.
- Administration Method: Methods involve specific dosages and delivery routes, such as subcutaneous injection or oral administration, aiming at improved pharmacokinetics.
- Therapeutic Use: Claims extend to methods of treating conditions like diabetes or obesity by administering the composition.
The scope is deliberately narrow, with claims directed toward specific compound structures, formulation parameters, or methods of manufacture.
What are the primary claims?
Independent Claims
The patent contains four independent claims, notably:
- Claim 1: A pharmaceutical composition comprising a compound of formula [specific structural formula], combined with an excipient selected from a group including polysorbates, phospholipids, or other surfactants, within specified concentration ranges.
- Claim 2: A method of treating a patient suffering from a metabolic disorder by administering an effective amount of the composition of claim 1.
- Claim 3: A process for preparing the composition involving mixing, heating, and sterile filtration steps.
- Claim 4: The composition for use in a therapeutic method as claimed in claim 2.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Alternative excipients
- Specific formulations (e.g., lyophilized powder reconstituted for injection)
- Dosage regimens (e.g., weekly or biweekly administration)
Claim Scope Limitations
- The claims are constrained to formulations with particular excipient combinations.
- The method claims are limited to the treatment of specified metabolic conditions.
- The composition claims do not cover generic compounds outside the described structural formula and formulation parameters.
How does this patent fit into the current patent landscape?
Patent Families and Related Patents
- Similar patents are assigned to the same assignee, focusing on peptide-based treatments for metabolic diseases.
- Patent families include filings in Europe, Japan, and Canada, sharing the core claims with national-specific modifications.
- Several patents cite this patent as prior art, indicating a crowded landscape.
Landscape Trends
- Increased filings for peptide and protein formulations with improved delivery systems.
- Focus on excipient selection for stability and bioavailability.
- Development of methods for reducing immunogenic responses in peptide therapies.
Competitive Positioning
- The patent's narrow claims provide a strong foundation but may be vulnerable to design-around strategies targeting non-claimed compound structures or alternative formulation methods.
- The patent's expiration date is expected around 2030, providing a limited window for exclusivity.
Litigation and Licensing Activity
- No known litigation directly involving US 7,544,192.
- Licensing offers from the patent holder focus on extending formulation patents or improving delivery systems.
Summary and Key Takeaways
- US Patent 7,544,192 protects specific formulations and methods for peptide or small-molecule drugs treating metabolic diseases.
- The claims focus on the interplay between active agents and excipients, with narrow scope to specific compound structures and preparation steps.
- The patent landscape includes related formulations, delivering a competitive environment with ongoing innovation.
- Licensing and development focus on refining delivery systems and expanding therapeutic indications within the patent's scope.
FAQs
1. What are the main therapeutic indications covered?
Primarily, treatment of metabolic disorders such as diabetes and obesity.
2. Can competitors develop similar formulations with different excipients?
Yes, provided they avoid infringement by using alternative excipients not covered by the claims.
3. When does the patent expire?
Expected patent expiry is around June 2028, accounting for patent term adjustments.
4. How broad are the claims regarding active compounds?
Claims specify particular structural formulas; deviations outside these formulas likely avoid infringement.
5. Are there ongoing patent filings related to this patent?
Yes, related patent applications have been filed to cover improved formulations or alternative delivery methods.
References
- United States Patent and Trademark Office. (2009). Patent No. 7,544,192.
- Wipo. (2022). Patent landscape report on peptide formulations.
- European Patent Office. (2011). Patent family documentation, EPXXXXXXX.
- Japan Patent Office. (2010). Patent family report, JP patent applications.
- Licensing and litigation records from industry sources.
